ArticleNorthern clinics of Istanbul2026
Diagnostic and predictive value of the hemoglobin-albumin-lymphocyte-platelet score in thyroid nodules: A retrospective analysis of 521 patients.
Article in Northern clinics of Istanbul, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe hemoglobin-albumin-lymphocyte-platelet (HALP) score, an integrated immunonutritional index, has shown significant prognostic value in several aggressive solid tumors. However, its role in the diagnostic workup and predictive stratification of thyroid cancer remains underexplored. This study aimed to comprehensively evaluate the diagnostic efficacy of the pre-operative HALP score and its association with lymph node metastasis (LNM) in patients undergoing thyroidectomy.
methodsWe retrospectively reviewed 521 consecutive patients who underwent thyroid surgery between 2022 and 2024. Pre-operative laboratory parameters, including thyroid-stimulating hormone (TSH), fT4, albumin, and complete blood count, were recorded. The HALP score was calculated as (Hemoglobin×Albumin×Lymphocytes)/Platelets. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis in combination with multivariate logistic regression. A subgroup analysis was performed for malignant cases to evaluate predictors of LNM.
resultsOf the cohort, 210 (40.3%) patients had malignant pathology. While serum TSH (p<0.001) and fT4 (p=0.043) were significantly higher in the malignant group, the HALP score demonstrated no significant difference (50.8±17.9 vs. 51.2±18.4, p=0.694). ROC analysis yielded an area under the curve of 0.510 for the HALP score, indicating a lack of discriminative power. In multivariate analysis, only Bethesda categories V (odds ratio [OR]: 17.48) and VI (OR: 104.29) were independent predictors of malignancy. For LNM, younger age (p=0.005), higher TSH (p=0.036), and lymphovascular invasion (p<0.001) were significant predictors, whereas the HALP score showed no predictive value (p=0.919).
conclusionThe pre-operative HALP score does not serve as a reliable diagnostic or predictive biomarker for thyroid malignancy or LNM. Pre-operative stratification should remain focused on cytopathology and established clinical-ultrasonographic risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.